Results 111 to 120 of about 12,230 (281)

Comparison of antianginal and antiischemic efficacy of cytoprotectors, nitrates, and beta-blockers during monotherapy and combined therapy in patients with effort angina and silent myocardial ischemia episodes

Российский кардиологический журнал, 2004
In 57 patients with stable effort angina, functional class II-III, and episodes of silent myocardial ischemia, antianginal and antiischemic efficacy of trimetazidine, isosorbide-5-mononitrate, and nadolol (monotherapy and combined therapy) was compared ...
S. N. Vaslyaeva, O. V. Zygankova, I. G. Gordeev, N. A. Volov   +3 more
doaj  

Old and new intravenous inotropic agents in the treatment of advanced heart failure [PDF]

, 2011
Inotropic agents are administered to improve cardiac output and peripheral perfusion in patients with systolic dysfunction and low cardiac output. However, there is evidence of increased mortality and adverse effects associated with current inotropic ...
Bettari L, Carubelli V, Dei Cas L., Metra M   +3 more
core   +1 more source

Effectiveness of the original trimetazidine MR in patients with stable coronary heart disease and angina attacks resistant to trimetazidine generics (ETALON study)

Кардиоваскулярная терапия и профилактика, 2011
Aim. To assess the clinical benefits of the original trimetazidine medication (Preductal® MR) in patients with stable coronary heart disease and angina attacks resistant to trimetazidine generics. Material and methods.
A. V. Fendrikova, V. V. Skibitskyi
doaj   +1 more source

The role of metabolic remodeling in macrophage polarization and its effect on skeletal muscle regeneration [PDF]

, 2019
Macrophages are crucial for tissue homeostasis. Based on their activation, they might display classical/M1 or alternative/M2 phenotypes. M1 macrophages produce pro-inflammatory cytokines, reactive oxygen species (ROS), and nitric oxide (NO).
Alessio Torcinaro, Elisabetta Ferraro, Fielding RA, Francesca De Santa, Galván-Peña S, Hard GC, Huang X, Kawanishi N, Laura Vitiello, Munder M, Ménégaut L, Ohtsu A, Tidball JG, Zhang X   +13 more
core   +1 more source

Therapeutic drug monitoring and pharmacogenomic guided perhexiline therapy in kidney failure requiring haemodialysis: a case study

Journal of Pharmacy Practice and Research, Volume 55, Issue 3, Page 244-247, June 2025.
Abstract Background Ischaemic heart disease is a leading cause of morbidity and mortality in haemodialysis patients, yet conventional therapies are often precluded due to increased perioperative risk and medication contraindications. Perhexiline, an antianginal agent, is contraindicated in renal impairment.
Harry Ashton, Hemant Kulkarni
wiley   +1 more source

Trimetazidine effects on intracellular Са2+ ion concentration in HL-60 human promyelocytes

Кардиоваскулярная терапия и профилактика, 2008
Aim. To investigate the effects of an anti-ischemic medication trimetazidine on Са2+ ion metabolism in human leukocyte and monocyte precursors – HL-60 promyelocytes.Material and methods. HL-60 cells were cultivated in vitro. Changes in intracellular free
E. I. Astashkin, M. G. Glezer, S. V. Grachev   +2 more
doaj  

Myocardial substrate metabolism in the normal and failing heart [PDF]

, 2005
The alterations in myocardial energy substrate metabolism that occur in heart failure, and the causes and consequences of these abnormalities, are poorly understood.
LOPASCHUK G.D., RECCHIA, FABIO ANASTASIO, STANLEY WC   +2 more
core   +1 more source

How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC

European Journal of Heart Failure, Volume 27, Issue 5, Page 747-759, May 2025.
Linking guideline‐directed medical therapy (GDMT) implementation and appropriate polypharmacy management in heart failure (HF). Polypharmacy can represent a barrier to the proper implementation of life‐prolonging GDMT for HF. A reasonable balance between the optimization of GDMT and avoiding inappropriate polypharmacy is mandatory in the contemporary ...
Davide Stolfo, Massimo Iacoviello, Ovidiu Chioncel, Markus S. Anker, Antoni Bayes‐Genis, Frieder Braunschweig, Antonio Cannata, Seif El Hadidi, Gerasimos Filippatos, Pardeep Jhund, Alexandre Mebazaa, Brenda Moura, Massimo Piepoli, Robin Ray, Arsen D. Ristic, Petar Seferovic, Maggie Simpson, Hadi Skouri, Carlo Gabriele Tocchetti, Sophie Van Linthout, Cristiana Vitale, Maurizio Volterrani, Kalliopi Keramida, Sven Wassmann, Basil S. Lewis, Marco Metra, Giuseppe M.C. Rosano, Gianluigi Savarese   +27 more
wiley   +1 more source

Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy – Six months follow-up result

Indian Heart Journal, 2016
Background: Ischemic cardiomyopathy is a growing burden in third world countries. So far, benefits of trimetazidine in this group of patients have been suggested by clinical trials mainly conducted in Europe.
A. Momen, M. Ali, P.K. Karmakar, M.Z. Ali, A. Haque, M.R. Khan, M.I. Khalil, M.S. Hossain, R.M. Huda, M.N. Goni   +9 more
doaj   +1 more source

Ranolazine: a new possibility and a new mechanism in the treatment of chronic angina pectoris. [PDF]

, 2011
In treatment of chronic angina pectoris in the last few years, besides the medicines with antianginal effect (adrenergic receptor beta blockers, calcium antagonists and nitrates) even ranolazine may be applied.
Goran Krstačić
core   +1 more source